Recent research reveals promising strategies against glioblastoma and other cancers: a study uncovers how glioblastoma cells detach and increase lethality via cellular plasticity; another identifies NUAK2 as a fetal oncogene and potential therapeutic target in glioblastoma; and molecular investigations highlight mechanisms behind immunotherapy failures. Collectively, these breakthroughs provide new insights into tumor adaptability, resistance, and immune evasion, opening avenues for next-generation cancer therapies to address the poor prognosis characteristic of aggressive malignancies.